Therapeutic efficacy of FASN inhibition in preclinical models of HCC
H Wang, Y Zhou, H Xu, X Wang, Y Zhang, R Shang… - Hepatology, 2022 - journals.lww.com
Conclusions This preclinical study suggests the limited efficacy of targeting FASN as
monotherapy for HCC treatment. However, FASN inhibitors could be combined with other
drugs for improved effectiveness. These combination therapies could be developed based
on the driver oncogenes, supporting precision medicine approaches for HCC treatment.
monotherapy for HCC treatment. However, FASN inhibitors could be combined with other
drugs for improved effectiveness. These combination therapies could be developed based
on the driver oncogenes, supporting precision medicine approaches for HCC treatment.